2020 SILVER SPONSOR

Terumo Corporation is a global leader in the medical device industry and is dedicated to developing innovative technologies for the treatment of cardiovascular disease.  Every year the company invests significant resources into the research and development of new products. As a result, Terumo’s perfusion portfolio for cardiac surgery is one of the most comprehensive in the industry.

The Capiox® range of oxygenators includes the FX Advance (FX25 & FX15) with integrated filter and self-venting technology which helps clinicians reduce prime volume lowering hemodilution (1). This results in fewer blood transfusions and reduced hospital costs (2).

Terumo’s CDI® 550 Blood Parameter Monitoring System provides critical information required for goal directed therapy, helping to achieve optimal perfusion during cardiopulmonary bypass surgery. In addition to all parameters available on the previous CDI 500, the CDI 550 provides continuous monitoring of DO2. Numerous clinical studies have demonstrated that careful monitoring of DO2 during CPB dramatically reduces kidney injury and leads to better patient outcomes (3, 4).

Our mission is to work as a team to save one more life, today and every day. We do this by providing lifesaving technology to cardiac surgery teams. Terumo is proud to sponsor the Society of Clinical Perfusion Scientists of Great Britain and Ireland meeting 2020. More information about our full range of products and services is available here.

Please contact Gemma Murphy, CV Marketing Assistant – gemma.murphy@terumo-europe.com if you require further information.

References:

(1)    Ranucci, M., et al. Effects of priming volume reduction on allogeneic red blood cell transfusions and renal outcome after heart surgery. Perfusion. March 2015; 30(2).

(2)    Lahanas, A., et al. A retrospective comparison of blood transfusion requirements during cardiopulmonary bypass with two different small adult oxygenators. Perfusion. July 2013; 28(4).

(3)    Ranucci M, et al. Effects of Priming Volume Reduction on Allogeneic Red Blood Cell Transfusions and Renal Outcome After Heart Surgery. Perfusion. 2015;30:120-126.

(4)     Dasta JF, Kane-Gill SL, Durtschi AJ, et al. Costs and Outcomes of Acute Kidney Injury (AKI) Following Cardiac Surgery. Nephrol Dial Transplant. 2008;23:1970-1974.

Please note the video below doesn't have sound.

VISIT SPONSOR WEBSITE

VIEW OUR 2020 SPONSORS